CN108785316A - 香加皮c21甾类在制备ido抑制剂中的用途 - Google Patents
香加皮c21甾类在制备ido抑制剂中的用途 Download PDFInfo
- Publication number
- CN108785316A CN108785316A CN201710292602.2A CN201710292602A CN108785316A CN 108785316 A CN108785316 A CN 108785316A CN 201710292602 A CN201710292602 A CN 201710292602A CN 108785316 A CN108785316 A CN 108785316A
- Authority
- CN
- China
- Prior art keywords
- periplocoside
- steroids
- cortex periplocae
- ido
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003431 steroids Chemical class 0.000 title claims abstract description 46
- 239000003112 inhibitor Substances 0.000 title claims abstract description 28
- OKQKFNTWEWCEEK-UHFFFAOYSA-N 6-[[17-hydroxy-17-[1-[5'-(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy-4'-methoxy-6',9-dimethylspiro[4,5a,6,7,9,9a-hexahydropyrano[3,4-c][1,2,5]trioxepine-3,2'-oxane]-7-yl]oxyethyl]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanth Chemical compound O1C(C)C(O)C(OC)CC1OC1C(OC)CC2(OOC3C(C)OC(OC(C)C4(O)C5(CCC6C7(C)CCC(CC7=CCC6C5CC4)OC4C(C(OC)=CC(C)O4)=O)C)CC3OC2)OC1C OKQKFNTWEWCEEK-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229930186642 periplocoside Natural products 0.000 claims abstract description 40
- KWBPKUMWVXUSCA-AXQDKOMKSA-N 3-[(3s,5s,8r,9s,10r,13r,14s,17r)-5,14-dihydroxy-3-[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] Chemical compound C1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@@H](C[C@@]5(O)CC[C@H]4[C@@]3(O)CC2)O[C@H]2C[C@@H]([C@@H]([C@@H](C)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)OC)=CC(=O)OC1 KWBPKUMWVXUSCA-AXQDKOMKSA-N 0.000 claims abstract description 34
- MQSVACYEBUOKAY-AEAHGDTJSA-N (2S,3S,4S,6R)-6-[(1S)-1-[(3S,8R,9S,10R,13S,14S,17R)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethoxy]-2-methyloxane-3,4-diol Chemical compound O([C@@H](C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1)[C@H]1O[C@@H](C)[C@@H](O)[C@@H](O)C1 MQSVACYEBUOKAY-AEAHGDTJSA-N 0.000 claims abstract description 18
- OPDVJOHDZLWTNG-UHFFFAOYSA-N 6-[[17-hydroxy-17-[1-[5-hydroxy-4-(methoxymethoxy)-6-methyloxan-2-yl]oxyethyl]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-methoxy-2-methyl-2h-pyran-5-one Chemical compound O1C(C)C(O)C(OCOC)CC1OC(C)C1(O)C2(C)CCC3C4(C)CCC(OC5C(C(OC)=CC(C)O5)=O)CC4=CCC3C2CC1 OPDVJOHDZLWTNG-UHFFFAOYSA-N 0.000 claims abstract description 18
- FKEFEVSJQJDJAJ-UHFFFAOYSA-N 6-[[17-[1-[5'-[5-[5-[5-(3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl)oxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-4'-methoxy-6',9-dimethylspiro[4,5a,6,7,9,9a-hexahydropyrano[3,4-c][1,2,5]trioxepine-3,2'- Chemical compound O1C(C)C(OC2OC(C)C(OC3C(C(OC)C(O)C(C)O3)O)C(OC)C2)C(OC)CC1OC(C(C1)OC)C(C)OC1OC(C(C1)OC)C(C)OC1(OOC1C(C)O2)COC1CC2OC(C)C(C1(CCC2C3(C)CC4)C)(O)CCC1C2CC=C3CC4OC1OC(C)C=C(OC)C1=O FKEFEVSJQJDJAJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- FKEFEVSJQJDJAJ-QEXOYQNYSA-N Periplocoside D Natural products O([C@H](C)[C@@]1(O)[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O[C@@H]3C(=O)C(OC)=C[C@H](C)O3)CC4)CC2)CC1)[C@H]1O[C@@H](C)[C@@H]2OO[C@@]3(O[C@@H](C)[C@@H](O[C@H]4O[C@@H](C)[C@@H](O[C@@H]5O[C@H](C)[C@H](O[C@H]6O[C@@H](C)[C@@H](O[C@@H]7[C@@H](O)[C@H](OC)[C@@H](O)[C@H](C)O7)[C@H](OC)C6)[C@H](OC)C5)[C@H](OC)C4)[C@H](OC)C3)CO[C@@H]2C1 FKEFEVSJQJDJAJ-QEXOYQNYSA-N 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 14
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims abstract description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- CGUNKFNCRCGQRL-COZUSOCZSA-N Periplocoside M Natural products O([C@H](C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O[C@H]3C(=O)C(OC)=C[C@H](C)O3)CC4)CC2)CC1)[C@H]1O[C@@H](C)[C@@H](O)[C@@H](O)C1 CGUNKFNCRCGQRL-COZUSOCZSA-N 0.000 claims abstract description 10
- 201000011510 cancer Diseases 0.000 claims abstract description 10
- ANPWGRGMIZXAAS-NCYFTHNPSA-N periplocoside P Natural products CO[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@@H]3[C@@H](C)O[C@@]4(CO[C@@H]5C[C@H](O[C@@H](C)[C@@]6(O)CC[C@H]7[C@@H]8CC=C9C[C@@H](O)CC[C@]9(C)[C@H]8CC[C@]67O)O[C@H](C)[C@H]5OO4)C[C@H]3OC)O[C@@H]2C)O[C@H](C)[C@H]1O[C@H]%10C[C@H](OC)[C@H](O[C@@H]%11O[C@H](C)[C@H](O)[C@H](OC)[C@H]%11OC)[C@@H](C)O%10 ANPWGRGMIZXAAS-NCYFTHNPSA-N 0.000 claims abstract description 9
- 208000002177 Cataract Diseases 0.000 claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 6
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 6
- 208000020401 Depressive disease Diseases 0.000 claims abstract description 6
- 208000019022 Mood disease Diseases 0.000 claims abstract description 6
- 230000003001 depressive effect Effects 0.000 claims abstract description 6
- 208000024732 dysthymic disease Diseases 0.000 claims abstract description 6
- 208000015238 neurotic disease Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 230000037353 metabolic pathway Effects 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000003147 glycosyl group Chemical group 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 10
- 230000007170 pathology Effects 0.000 claims 2
- 239000006072 paste Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 23
- 230000003834 intracellular effect Effects 0.000 abstract description 8
- 239000013641 positive control Substances 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 55
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 55
- 239000012071 phase Substances 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 229930188825 Periploside Natural products 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 238000010828 elution Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 12
- 206010061372 Streptococcal infection Diseases 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000753128 Periploca <moth> Species 0.000 description 9
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 9
- 0 C*[C@](CC[C@](N)[U]1)C1=CC Chemical compound C*[C@](CC[C@](N)[U]1)C1=CC 0.000 description 8
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001406327 Periploca sepium Species 0.000 description 7
- 229930182470 glycoside Natural products 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108010025832 RANK Ligand Proteins 0.000 description 6
- 102000014128 RANK Ligand Human genes 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- -1 emplastrum Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- SRHLMPMVONOECX-PSZRWYKPSA-N [(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,6S)-6-[(2R,3R,4S,6S)-6-[(2R,3R,4S,6S)-6-[(2'R,3'R,4R,4'R,5aR,6R,8S,9aR)-8-[(1S)-1-[(3S,8R,9S,10R,13S,14S,17R)-17-hydroxy-3-[[(2R,6R)-4-methoxy-2-methyl-5-oxo-2H-pyran-6-yl]oxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethoxy]-4'-methoxy-2',6-dimethylspiro[6,8,9,9a-tetrahydro-5aH-pyrano[3,4-f][1,3,5]trioxepine-4,6'-oxane]-3'-yl]oxy-4-methoxy-2-methyloxan-3-yl]oxy-4-methoxy-2-methyloxan-3-yl]oxy-4-methoxy-2-methyloxan-3-yl]oxy-5-hydroxy-4-methoxy-6-methyloxan-3-yl] acetate Chemical compound CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)O[C@H](C[C@@H]2OC)O[C@@H]2[C@@H](C)O[C@@]3(C[C@H]2OC)OCO[C@@H]2C[C@H](O[C@@H](C)[C@@]4(O)CC[C@H]5[C@@H]6CC=C7C[C@H](CC[C@]7(C)[C@H]6CC[C@]45C)O[C@@H]4O[C@H](C)C=C(OC)C4=O)O[C@H](C)[C@H]2O3)O[C@H](C)[C@H]1O[C@H]1C[C@H](OC)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](OC)[C@H]2OC(C)=O)[C@@H](C)O1 SRHLMPMVONOECX-PSZRWYKPSA-N 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- ZNQVDNYGPSXRAP-WYQXTEGQSA-N (2R,6R)-6-[[(3S,8R,9S,10R,13S,14S,17R)-17-[(1S)-1-[(4R,4'R,5'R,5aR,6R,6'R,8S,9aR)-5'-[(2S,4S,5R,6R)-5-[(2S,4R,5S,6R)-5-[(2S,4S,5R,6R)-5-[(2S,3R,4S,5S,6R)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-4'-methoxy-6,6'-dimethylspiro[6,8,9,9a-tetrahydro-5aH-pyrano[3,4-f][1,3,5]trioxepine-4,2'-oxane]-8-yl]oxyethyl]-17-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-methoxy-2-methyl-2H-pyran-5-one Chemical compound CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)O[C@@]3(C[C@H]2OC)OCO[C@@H]2C[C@H](O[C@@H](C)[C@@]4(O)CC[C@H]5[C@@H]6CC=C7C[C@H](CC[C@]7(C)[C@H]6CC[C@]45C)O[C@@H]4O[C@H](C)C=C(OC)C4=O)O[C@H](C)[C@H]2O3)O[C@H](C)[C@H]1O[C@H]1C[C@@H](O)[C@H](O[C@H]2C[C@H](OC)[C@H](O[C@@H]3O[C@H](C)[C@H](O)[C@H](OC)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1 ZNQVDNYGPSXRAP-WYQXTEGQSA-N 0.000 description 4
- KMYPXJHTRBQNTM-VGDNXOMPSA-N (2R,6R)-6-[[(3S,8R,9S,10R,13S,14S,17R)-17-[(1S)-1-[(4R,4'R,5'R,5aR,6R,6'R,8S,9aR)-5'-[(2S,4S,5S,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,3R,4S,5S,6R)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4'-methoxy-6,6'-dimethylspiro[6,8,9,9a-tetrahydro-5aH-pyrano[3,4-f][1,3,5]trioxepine-4,2'-oxane]-8-yl]oxyethyl]-17-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-methoxy-2-methyl-2H-pyran-5-one Chemical compound CO[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@@H]3[C@@H](C)O[C@@]4(C[C@H]3OC)OCO[C@@H]3C[C@H](O[C@@H](C)[C@@]5(O)CC[C@H]6[C@@H]7CC=C8C[C@H](CC[C@]8(C)[C@H]7CC[C@]56C)O[C@@H]5O[C@H](C)C=C(OC)C5=O)O[C@H](C)[C@H]3O4)O[C@@H]2C)O[C@H](C)[C@H]1O[C@H]1C[C@H](OC)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](OC)[C@H]2O)[C@@H](C)O1 KMYPXJHTRBQNTM-VGDNXOMPSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- IGIUHSFSLKWBAJ-OVXUJRNUSA-N [(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,6S)-6-[(2R,3R,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2'R,3'R,4R,4'R,5aR,6R,8S,9aR)-8-[(1S)-1-[(3S,8R,9S,10R,13S,14S,17R)-17-hydroxy-3-[[(2R,6R)-4-methoxy-2-methyl-5-oxo-2H-pyran-6-yl]oxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethoxy]-4'-methoxy-2',6-dimethylspiro[6,8,9,9a-tetrahydro-5aH-pyrano[3,4-f][1,3,5]trioxepine-4,6'-oxane]-3'-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-4-methoxy-2-methyloxan-3-yl]oxy-4-methoxy-2-methyloxan-3-yl]oxy-5-hydroxy-4-methoxy-6-methyloxan-3-yl] acetate Chemical compound CO[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@@H]3[C@@H](C)O[C@@]4(C[C@H]3OC)OCO[C@@H]3C[C@H](O[C@@H](C)[C@@]5(O)CC[C@H]6[C@@H]7CC=C8C[C@H](CC[C@]8(C)[C@H]7CC[C@]56C)O[C@@H]5O[C@H](C)C=C(OC)C5=O)O[C@H](C)[C@H]3O4)O[C@@H]2C)O[C@H](C)[C@H]1O[C@H]1C[C@H](OC)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](OC)[C@H]2OC(C)=O)[C@@H](C)O1 IGIUHSFSLKWBAJ-OVXUJRNUSA-N 0.000 description 4
- HNVWMDXDTMOSDS-QGUSWZPOSA-N [(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,6S)-6-[(2R,3S,4R,6S)-6-[(2R,3R,4S,6S)-6-[(2'R,3'R,4R,4'R,5aR,6R,8S,9aR)-8-[(1S)-1-[(3S,8R,9S,10R,13S,14S,17R)-17-hydroxy-3-[[(2R,6R)-4-methoxy-2-methyl-5-oxo-2H-pyran-6-yl]oxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethoxy]-4'-methoxy-2',6-dimethylspiro[6,8,9,9a-tetrahydro-5aH-pyrano[3,4-f][1,3,5]trioxepine-4,6'-oxane]-3'-yl]oxy-4-methoxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-4-methoxy-2-methyloxan-3-yl]oxy-5-hydroxy-4-methoxy-6-methyloxan-3-yl] acetate Chemical compound CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)O[C@@]3(C[C@H]2OC)OCO[C@@H]2C[C@H](O[C@@H](C)[C@@]4(O)CC[C@H]5[C@@H]6CC=C7C[C@H](CC[C@]7(C)[C@H]6CC[C@]45C)O[C@@H]4O[C@H](C)C=C(OC)C4=O)O[C@H](C)[C@H]2O3)O[C@H](C)[C@H]1O[C@H]1C[C@@H](O)[C@H](O[C@H]2C[C@H](OC)[C@H](O[C@@H]3O[C@H](C)[C@H](O)[C@H](OC)[C@H]3OC(C)=O)[C@@H](C)O2)[C@@H](C)O1 HNVWMDXDTMOSDS-QGUSWZPOSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229930190426 periperoxide Natural products 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WITLAWYGGVAFLU-UHFFFAOYSA-N 3-(6-methoxy-1,3-benzodioxol-5-yl)-8,8-dimethylpyrano[2,3-f]chromen-4-one Chemical compound C1=CC(C)(C)OC2=CC=C(C(C(C3=CC=4OCOC=4C=C3OC)=CO3)=O)C3=C21 WITLAWYGGVAFLU-UHFFFAOYSA-N 0.000 description 2
- LPSOSXGOHMUVDT-UHFFFAOYSA-N 6-[[17-hydroxy-17-[1-[5'-[5-(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy-4-methoxy-6-methyloxan-2-yl]oxy-4'-methoxy-6',9-dimethylspiro[4,5a,6,7,9,9a-hexahydropyrano[3,4-c][1,2,5]trioxepine-3,2'-oxane]-7-yl]oxyethyl]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15, Chemical compound O1C(C)C(O)C(OC)CC1OC1C(OC)CC(OC2C(CC3(OC2C)OOC2C(C)OC(OC(C)C4(O)C5(CCC6C7(C)CCC(CC7=CCC6C5CC4)OC4C(C(OC)=CC(C)O4)=O)C)CC2OC3)OC)OC1C LPSOSXGOHMUVDT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000208327 Apocynaceae Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- QYKQWFZDEDFELK-UHFFFAOYSA-N brassinin Chemical compound C1=CC=C2C(CNC(=S)SC)=CNC2=C1 QYKQWFZDEDFELK-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229950009034 indoximod Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- DSYKJFFQHNSURC-UHFFFAOYSA-N methyl 6-ethyl-5-hydroxy-3-methoxy-1,1,7-trimethyl-4,9-dioxobenzo[f][2]benzofuran-3-carboxylate Chemical compound O=C1C2=C(O)C(CC)=C(C)C=C2C(=O)C2=C1C(OC)(C(=O)OC)OC2(C)C DSYKJFFQHNSURC-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000325586 Neopetrosia exigua Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- RTMAZVHPRZLMEU-WPLROGRBSA-N Periplocoside A Natural products O=C(O[C@H]1[C@H](OC)[C@@H](O)[C@@H](C)O[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](C)O[C@@H](O[C@H]3[C@@H](C)O[C@H](O[C@H]4[C@H](C)O[C@@]5(OO[C@@H]6[C@@H](C)O[C@H](O[C@H](C)[C@]7(O)[C@]8(C)[C@@H]([C@@H]9[C@H]([C@@]%10(C)C(=CC9)C[C@H](O[C@H]9C(=O)C(OC)=C[C@H](C)O9)CC%10)CC8)CC7)C[C@H]6OC5)C[C@@H]4OC)C[C@H]3OC)C[C@@H]2OC)C[C@H]1OC)C RTMAZVHPRZLMEU-WPLROGRBSA-N 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- RTMAZVHPRZLMEU-UHFFFAOYSA-N [5-hydroxy-2-[6-[6-[6-[7-[1-[17-hydroxy-3-[(4-methoxy-2-methyl-5-oxo-2h-pyran-6-yl)oxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethoxy]-4'-methoxy-2',9-dimethylspiro[4,5a,6,7,9,9a-hexahydropyrano[3,4-c][1,2,5] Chemical compound O1C(C)C(OC2OC(C)C(OC3C(C(OC)C(O)C(C)O3)OC(C)=O)C(OC)C2)C(OC)CC1OC(C(C1)OC)C(C)OC1OC(C(C1)OC)C(C)OC1(OOC1C(C)O2)COC1CC2OC(C)C(C1(CCC2C3(C)CC4)C)(O)CCC1C2CC=C3CC4OC1OC(C)C=C(OC)C1=O RTMAZVHPRZLMEU-UHFFFAOYSA-N 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000026 apposition eye Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- UEKKREMMIOJMRO-RUZDIDTESA-O exiguamine A Chemical compound O=C1N(C)C(=O)N(C)[C@@]11C(C(=O)C2=C(NC=C2CCN)C2=O)=C2C2=C(CC[N+]3(C)C)C3=CC(O)=C2O1 UEKKREMMIOJMRO-RUZDIDTESA-O 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- 239000007691 rabbit blood agar Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical class [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical class OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于药品或保健品领域，具体涉及香加皮C21甾类在制备IDO抑制剂中的用途。本发明通过研究发现，杠柳苷C、杠柳苷D、杠柳苷O、杠柳苷P、杠柳苷Q、杠柳苷R、杠柳苷S、杠柳苷M和杠柳苷N对细胞内的IDO的抑制活性均优于阳性对照药1‑甲基色氨酸(1‑MT)对细胞内的IDO的抑制活性，具有显著的IDO的抑制活性，可以用于治疗癌症、阿尔茨海默病、自身免疫性疾病、强直性脊柱炎、细菌感染、白内障、心境障碍、抑郁症或焦虑症。
Description
技术领域
本发明属于药品或保健品领域，具体涉及香加皮C21甾类在制备IDO抑制剂中的用途。
背景技术
IDO(indoleamine-2，3-dioxygenase)中文名为吲哚胺2，3-双加氧化酶，是肝脏以外唯一催化色氨酸沿犬尿氨酸途径(kynurenine pathway，KP)代谢的限速酶，可以将色氨酸分解为L-犬尿氨酸、吡啶甲酸和喹啉酸等多种代谢物。L-色氨酸作为人体内维持细胞活化和增殖所必需的氨基酸，也是构成蛋白质不可缺少的成分，它的缺乏会导致一些重要细胞的功能异常。自1967年被发现以来，IDO通过降解色氨酸抑制病原微生物增殖的机制、IDO与神经系统疾病之间的关系逐渐被阐明；并有研究证实，IDO还参与调节T细胞的反应，能够对T细胞的增殖和活化产生抑制作用，而这种抑制作用则介导了表达IDO肿瘤细胞的免疫逃逸现象。因此，IDO的表达或活性的异常增高，与多种疾病的发病机制密切相关，是导致多种疾病的重要因素，例如已被证实的肿瘤、阿尔茨海默病、抑郁症和老年性白内障、AIDS等病毒感染、莱姆病和链球菌感染等细菌感染等(可参考如下文献：IDO抑制剂的研究进展，孔令雷等，《中国药物化学杂志》，2009，19(2)：147-154；中国专利文献CN101429151A一种含(E)-4-(Β-溴乙烯基)苯氧酰基结构的IDO抑制剂及其制备方法，公开日期2009年5月13日)。因此，IDO抑制剂成为极具潜力的治疗药物，引起了众多学者的关注。
作为一种全新靶点，IDO成为极具潜力的癌症免疫治疗靶标。筛选高效、低毒的IDO抑制剂/抗体，并将其用于治疗上述疾病，成为了研究人员的共同诉求。1978年，有研究人员研究分离出了非选择性的竞争性IDO抑制剂，但其抑制效力微弱。20世纪90年代初，首次合成了色氨酸衍生物1-MT(即：indoximod)，其作为与底物色氨酸结构最接近的抑制剂，引起了人们对于IDO抑制剂更为广泛的关注和兴趣。IDO抑制剂的研发尚处于药物开发的初期，目前仅有2个化合物(epacadostat和indoximod)进入Ⅱ期临床，1个化合物(GDC-0919)进入Ⅰ期临床。
最初寻找IDO抑制剂的工作主要以化学合成为手段，以IDO的底物色氨酸为模板，在研究构效关系的基础上对其进行结构修饰，发表的文章和注册的专利几乎覆盖了所有能修饰的基团，但是收效甚微。从2006年起，国内外学者们尝试从天然产物中寻找具有新结构骨架的高活性的IDO抑制剂，如：Brastianos等从海绵Neopetrosiaexigua中提取了得到Exiguamine A(Ki值＝0.21μM)；Alban Pereir等从海水螅中提取得到Annulin C(Ki值＝0.14μM)；Caspari等发现商业可售的天然产物Brassinin(Ki值＝97.7μM)具有中等活性；中国专利文献CN101843618A公开了：小檗碱及其衍生物亦具有IDO抑制作用。
香加皮，别名为北五加皮、香五加，来源于萝藦科(Asclepiadaceae)杠柳属(Periploca)植物杠柳(Periploca sepium Bunge)的干燥根皮。香加皮，性温，味辛、苦，有毒，具有祛风湿、强筋骨的功效，临床上中用于风寒湿痹、腰膝酸软、心悸气短、下肢浮肿的治疗；该药材是治疗类风湿性关节炎的传统中药，药理研究表明该药材具有抗炎和免疫抑制作用。从1987年日本学者发现该药材具有抗肿瘤作用以来，对该药材抗肿瘤活性成分及其作用机制的研究报道也逐渐增多。香加皮C21甾类是香加皮提取物中的成分。
目前，关于香加皮C21甾类用于制备IDO抑制剂尚无报道。
发明内容
为此，本发明要解决的技术问题是现有技术中无香加皮C21甾类用于制备IDO抑制剂的问题，从而提供香加皮C21甾类在制备IDO抑制剂中的用途。
为解决上述技术问题，本发明是通过以下技术方案来实现的：
本发明提供香加皮C21甾类及其药学上可接受的衍生物在制备IDO抑制剂中的用途；
所述IDO抑制剂用于治疗癌症、阿尔茨海默病、自身免疫性疾病、强直性脊柱炎、细菌感染、白内障、心境障碍、抑郁症或焦虑症；所述药学上可接受的衍生物选自盐、酯、前药或溶剂合物；
所述香加皮C21甾类具有如下所示的结构：
R选自及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物中的至少一种所形成的糖基残基。
本发明还提供香加皮C21甾类及其药学上可接受的衍生物在制备治疗IDO介导的色氨酸代谢途径的病理学特征的疾病的药品中的用途，所述疾病为癌症、阿尔茨海默病、自身免疫性疾病、强直性脊柱炎、细菌感染、白内障、心境障碍、抑郁症或焦虑症；所述药学上可接受的衍生物选自盐、酯、前药或溶剂合物；
所述香加皮C21甾类具有如下所示的结构：
R选自及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物中的至少一种所形成的糖基残基。
其中，糖的乙酰化衍生物是指：糖分子中的游离羟基(-OH)被乙酰基(-Ac)所保护的糖衍生物。
所述药学上可接受的盐，例如，是与盐酸、硫酸、磷酸、硝酸等无机酸形成的盐，或是与柠檬酸、琥珀酸、酒石酸、甲磺酸等有机酸形成的盐。
优选地，上述用途中，
R为时，所述香加皮C21甾类为杠柳苷C(Periploside C)；或者
R为时，所述香加皮C21甾类为杠柳苷D(Periploside D)；或者
R为时，所述香加皮C21甾类为杠柳苷O(Periploside O)；或者
R为时，所述香加皮C21甾类为杠柳苷P(Periploside P)；或者
R为时，所述香加皮C21甾类为杠柳苷Q(Periploside Q)；或者
R为时，所述香加皮C21甾类为杠柳苷R(Periploside R)；或者
R为时，所述香加皮C21甾类为杠柳苷S(Periploside S)；或者
R为时，所述香加皮C21甾类为杠柳苷M(Periploside M)；或者
R为时，所述香加皮C21甾类为杠柳苷N(Periploside N)。
根据文献(“Structural revision of periplocosides and periperoxides，natural immunosuppressive agents from the genus Periploca”，Luo-Yi Wang etal.，Phytochemistry，2011，72，2230-2236)的报道，本发明香加皮C21甾类中，杠柳苷C(Periploside C)曾用名为杠柳毒苷A(Periplocoside A)，杠柳苷D(Periploside D)曾用名为杠柳毒苷D(Periplocoside D)，杠柳苷M(Periploside M)曾用名为杠柳毒苷B(Periplocoside B)，杠柳苷N(Periploside N)曾用名为杠柳毒苷C(Periplocoside C)。
优选地，上述用途中，不包括以下技术方案：
杠柳苷C及其药学上可接受的衍生物在制备IDO抑制剂中的用途；所述IDO抑制剂用于治疗癌症或自身免疫性疾病；
杠柳苷D及其药学上可接受的衍生物在制备IDO抑制剂中的用途；所述IDO抑制剂用于治疗自身免疫性疾病。
优选地，上述用途中，不包括以下技术方案：
杠柳苷C及其药学上可接受的衍生物在制备治疗IDO介导的色氨酸代谢途径的病理学特征的疾病的药品中的用途，所述疾病为癌症或自身免疫性疾病；
杠柳苷D及其药学上可接受的衍生物在制备治疗IDO介导的色氨酸代谢途径的病理学特征的疾病的药品中的用途，所述疾病为自身免疫性疾病。
优选地，上述用途中，所述香加皮C21甾类按照常规工艺，加入常规辅料制成临床上可接受的片剂、胶囊剂、散剂、合剂、丸剂、颗粒剂、糖浆剂、贴膏剂、栓剂、气雾剂、软膏剂或注射剂。
所述常规辅料为：填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质等。填充剂包括：淀粉、预胶化淀粉、乳糖、甘露醇、甲壳素、微晶纤维素、蔗糖等；崩解剂包括：淀粉、预胶化淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙纤维素、交联羧甲基纤维素纳等；润滑剂包括：硬脂酸镁、十二烷基硫酸钠、滑石粉、二氧化硅等；助悬剂包括：聚乙烯吡咯烷酮、微晶纤维素、蔗糖、琼脂、羟丙基甲基纤维素等；粘合剂包括，淀粉浆、聚乙烯吡咯烷酮、羟丙基甲基纤维素等；甜味剂包括：糖精钠、阿斯帕坦、蔗糖、甜蜜素、甘草次酸等；矫味剂包括：甜味剂及各种香精；防腐剂包括：尼泊金类、苯甲酸、苯甲酸钠、山梨酸及其盐类、苯扎溴铵、醋酸氯乙定、桉叶油等；基质包括：PEG6000、PEG4000、虫蜡等。
本发明的技术方案具有如下优点：
本发明通过研究发现，杠柳苷C、杠柳苷D、杠柳苷O、杠柳苷P、杠柳苷Q、杠柳苷R、杠柳苷S、杠柳苷M和杠柳苷N对细胞内的IDO的抑制活性均优于阳性对照药1-甲基色氨酸(1-MT)对细胞内的IDO的抑制活性，具有显著的IDO的抑制活性，可以用于治疗癌症、阿尔茨海默病、自身免疫性疾病、强直性脊柱炎、细菌感染、白内障、心境障碍、抑郁症或焦虑症。
具体实施方式
本发明以下实施例和实验例中，杠柳苷C(Periploside C)、杠柳苷D(PeriplosideD)、杠柳苷O(Periploside O)、杠柳苷P(Periploside P)、杠柳苷Q(Periploside Q)、杠柳苷R(Periploside R)、杠柳苷S(Periploside S)、杠柳苷M(Periploside M)、杠柳苷N(Periploside N)可以按照本发明实施例1的方法进行制备获得，也可以按照如下文献制备获得：
Studies on chemical constituents of antitumor fraction from Periplocasepium BGE.I.Chemical&Pharmaceutical Bulletin，1987，35(11)，4524-4529.
Studies on chemical constituents of antitumor fraction from Periplocasepium.II.Structures of new pregnane glycosides,periplocosides A,B andC.Chemical&Pharmaceutical Bulletin，1988，36(3)，982-987.
Studies on chemical constituents of antitumor fraction from Periplocasepium.IV.Structures of new pregnane glycosides,periplocosides D,E,L,andM.Chemical&Pharmaceutical Bulletin，1988，36(6)，2084-2089.
Studies on chemical constituents of antitumor fraction from Periplocasepium.V.Structures of new pregnane glycosides，periplocosides J,K,F andO.Chemical&Pharmaceutical Bulletin，1988，36(11)，4441-4446.
Immunosuppressive pregnane glycosides from Periploca sepium andPeriploca forrestii.Phytochemistry，2008，69(15)，2716-2723.
Structural revision of periplocosides and periperoxides，naturalimmunosuppressive agents from the genus Periploca.Phytochemistry，2011，72(17)，2230-2236.
Corrigendum to“Structural revision of periplocosides andperiperoxides，natural immunosuppressive agents from the genus Periploca”[Phytochemistry 72/17(2011)2230–2236].Phytochemistry，2013，95，445.
高效液相色谱法测定中药香加皮中7种孕甾烷糖苷类成分的含量，《世界科学技术-中医药现代化》，2015，17(1)，138-141.
实施例1香加皮C21甾类的制备
取香加皮，粉碎，加入3倍重量的体积浓度为95％的乙醇水溶液加热回流提取3次，每次提取2小时，合并提取液，减压浓缩至无醇味，得香加皮浸膏；
将香加皮浸膏混悬于1倍重量的水中，然后以氯仿为萃取剂进行萃取2次，收集萃取液的有机相，然后进行减压浓缩，得香加皮氯仿萃取部位浸膏；
取香加皮氯仿萃取部位浸膏经AB-8大孔树脂柱层析纯化(大孔树脂柱的直径为8cm，柱体积为3.5L)，以水为流动相A、以乙醇为流动相B，按照如下程序进行梯度洗脱(梯度洗脱的流速为3BV/h)：先用A：B体积比为50％：50％的流动相洗脱5BV，再用A：B体积比为40％：60％的流动相洗脱5BV，再用A：B体积比为30％：70％的流动相洗脱5BV，再用A：B体积比为15％：85％的流动相洗脱5BV，再用A：B体积比为5％：95％的流动相洗脱5BV；分别收集流动相为A：B体积比为30％：70％、A：B体积比为15％：85％的洗脱液，然后分别进行减压浓缩，分别得香加皮乙醇洗脱部位浸膏-1和香加皮乙醇洗脱部位浸膏-2；
将香加皮乙醇洗脱部位浸膏-1经Agilent SD-1的C18反相制备液相分离纯化，以水为流动相C、以甲醇为流动相D，按照如下程序进行梯度洗脱：先用C：D体积比为70％：30％的流动相洗脱，再用C：D体积比为65％：35％的流动相洗脱，再用C：D体积比为60％：40％的流动相洗脱，再用C：D体积比为50％：50％的流动相洗脱，再用C：D体积比为40％：60％的流动相洗脱，通过TLC检测或HPLC-MS检测，分别收集各流动相的洗脱液，然后分别进行减压浓缩、干燥，分别得杠柳苷C(Periploside C)、杠柳苷O(Periploside O)、杠柳苷R(Periploside R)、杠柳苷M(Periploside M)、杠柳苷N(Periploside N)(HPLC纯度≥95％)；
将香加皮乙醇洗脱部位浸膏-2经Agilent SD-1的C18反相制备液相分离纯化，以水为流动相C、以甲醇为流动相D，按照如下程序进行梯度洗脱：先用C：D体积比为55％：45％的流动相洗脱，再用C：D体积比为45％：55％的流动相洗脱，再用C：D体积比为35％：65％的流动相洗脱，再用C：D体积比为20％：80％的流动相洗脱，通过TLC检测或HPLC-MS检测，分别收集各流动相的洗脱液，然后分别进行减压浓缩、干燥，分别得杠柳苷D(Periploside D)、杠柳苷P(Periploside P)、杠柳苷Q(Periploside Q)、杠柳苷S(Periploside S)(HPLC纯度≥95％)。
将上述制备得到的化合物分别通过1H-NMR、13C-NMR和HPLC-MS进行结构确认，通过与现有文献中的1H-NMR、13C-NMR和HPLC-MS分别进行比对，可知所制备得到的化合物分别为杠柳苷C(Periploside C)、杠柳苷D(Periploside D)、杠柳苷O(Periploside O)、杠柳苷P(Periploside P)、杠柳苷Q(Periploside Q)、杠柳苷R(Periploside R)、杠柳苷S(Periploside S)、杠柳苷M(Periploside M)、杠柳苷N(Periploside N)。
实验例1本发明香加皮C21甾类对IDO的抑制活性的研究
1、实验目的
利用质粒pcDNA3.1-IDO转染HEK293细胞，使其高表达IDO，然后测定本发明香加皮C21甾类在细胞水平对IDO的抑制活性。
2、实验方法
将HEK 293细胞以2.5X104细胞/孔的密度接种于96孔板中，DMEM培养基培养(含10％胎牛血清、50U/mL青霉素和50mg/mL链霉素)，置于37℃、湿度95％、5％CO2的培养箱中培养。培养24h后，使用脂质体Lipofectamin 2000介导pcDNA3.1-hIDO质粒转染，分为阳性对照组和实验组1-9组。
阳性对照组以1-甲基色氨酸(1-MT)为供试品，实验组1-9组分别以实施例1制备的杠柳苷C、杠柳苷D、杠柳苷O、杠柳苷P、杠柳苷Q、杠柳苷R、杠柳苷S、杠柳苷M、杠柳苷N为供试品。
转染24h后，各组分别加入对应的供试品进行孵育。孵育5h后，取140μL上清到另一96孔板中，加入10μL 30％(w/v)三氯乙酸，在65℃加热15min，然后12000rpm离心10min，取等体积2％(w/v)对-二甲氨基苯甲醛的乙酸溶液混合显色，最后采用酶标仪在492nm检测吸光值，活性测定结果用IC50值表示。
3、实验结果
各组对IDO的抑制活性的具体实验结果如表1所示。
表1各组对细胞水平IDO的抑制活性的具体实验结果
由表1可知：(1)实验组1-9组对细胞内的IDO的抑制活性均优于阳性对照组对细胞内的IDO的抑制活性，具有显著的IDO的抑制活性；
(2)实验组1-9组对细胞内的IDO的抑制活性相当，这表明香加皮C21甾类的R取代基的不同对抑制活性无明显影响。
4、实验结论
杠柳苷C、杠柳苷D、杠柳苷O、杠柳苷P、杠柳苷Q、杠柳苷R、杠柳苷S、杠柳苷M、杠柳苷N对细胞内的IDO的抑制活性均优于阳性对照药1-甲基色氨酸(1-MT)对细胞内的IDO的抑制活性，具有显著的IDO的抑制活性。
实验例2本发明香加皮C21甾类对强直性脊柱炎的治疗效果
1、实验目的
采用蛋白聚糖免疫方法建立小鼠强直性脊柱炎模型，然后灌胃本发明香加皮C21甾类，ELISA法检测炎性标志物血清TNF-α和NF-кB受体活化因子配体(RANKL)水平，并检测血清IDO活性(Kyn/Trp)，验证本发明香加皮C21甾类对于强直性脊柱炎的疗效。
2、实验方法
2.1实验动物
健康雄性BALB/c小鼠32只，体重(18±2)g，鼠龄4～5周，均购自上海斯莱克。
2.2供试药物
以实施例1制备的杠柳苷C和杠柳苷Q为供试药物。
2.3实验分组及造模
将小鼠适应性喂养1周后，取其中8只作为空白对照组。取剩余的24只采用蛋白聚糖免疫方法建立强直性脊柱炎模型，鼠腹腔注射蛋白聚糖乳剂0.15mL(75μg+弗氏佐剂)，首次免疫后7天可加强免疫，腹腔注射0.15mL乳剂，造模共21天；造模成功后，分为3组：实验组1-2组和模型对照组。实验组1-2组分别给予实施例1制备的杠柳苷C和杠柳苷Q灌胃给药，每日1次，每次0.2g/10g。模型对照组和空白对照组均给予等量生理盐水灌胃。各组均给药60天，于第61天眼眶取血。
2.4炎症因子测定
采用ELISA检测动物外周血中血清TNF-α和RANKL水平，按照试剂盒说明书操作。
2.5IDO活性检测
利用高效液相色谱技术同时检测小鼠血清中Trp浓度与Kyn浓度。因为IDO能催化底物Trp代谢生成产物Kyn，故Kyn/Trp比值可以反映IDO活性。
血清在4℃下放置过夜，3000rpm离心15min。取上清血清，加入等体积的5％高氯酸溶液，于漩祸混匀器上混匀0.5-1min。室温静置10-15min，以充分沉淀血清中的蛋白，然后以12000rpm离心10min，取上清液加入1/2体积甲醇(色谱纯)，在漩祸仪上振荡5min，然后12000rpm离心10min，最后上清经过0.45μm过滤器过滤后进行上样，检测血清中犬尿氨酸/色氨酸(Kyn/Trp)比值，从而反映IDO活性的变化。色谱条件：C18柱(250mm×4.6mm，5μm)；流动相：15mmol/L乙酸钠-乙酸溶液(含体积分数为7％的乙腈，pH 3.5)；流速：1mL/min；检测波长：225nm；进样量：20μL；柱温25℃。
2.6统计学处理
采用SPSS22.0统计学软件进行分析，计量数据用均数±标准差 表示，行t检验；计数资料用百分比表示，行χ2检验；P＜0.05表示差异有统计学意义。
3、实验结果
各组小鼠的具体实验结果如表2所示。
表2各组小鼠血清TNF-α和RANKL水平以及对IDO活性的抑制作用
#与空白对照组比较P＜0.05，*与模型对照组比较P＜0.05
由表2可知，(1)模型对照组小鼠的血清TNF-α和RANKL水平明显升高，这表明强直性脊柱炎模型造模成功；(2)实验组1-2组小鼠的血清TNF-α和RANKL水平显著降低(P＜0.05)，且显著降低IDO活性(P＜0.05)；这表明，实施例1制备的杠柳苷C和杠柳苷Q通过抑制IDO活性起到对强直性脊柱炎的治疗效果。
4、实验结论
本发明杠柳苷C和杠柳苷Q可以显著降低强直性脊柱炎模型的血清TNF-α和RANKL水平，且对IDO活性具有显著的抑制作用；本发明杠柳苷C和杠柳苷Q对强直性脊柱炎具有显著的治疗作用。
实验例3本发明香加皮C21甾类对于链球菌感染的治疗作用
1、实验目的
通过对链球菌感染小鼠灌胃本发明香加皮C21甾类，检测其对于链球菌感染小鼠的死亡抑制率，验证其对链球菌感染的治疗作用。
2、实验方法
2.1实验动物
健康雄性昆明小鼠40只，体重(18±2)g，鼠龄4～5周，均购自上海斯莱克。
2.2供试药物
以实施例1制备的杠柳苷C和杠柳苷Q为供试药物。
2.3实验分组及造模
溶血性链球菌CMCC(B)32171标准菌株接种兔血琼脂平板，划线后培养得到有明显溶血环的单菌落。取单菌落接种于THY培养基(含5％小牛血清)扩增过夜，OD600nm＝0.6(约109CFU/ml)时，4℃保存备用。THY培养基(每升含胰蛋白胨20克，酵母浸出物3克，牛肉膏5克，氯化钠2克，葡萄糖4克，碳酸钠2.5克，磷酸氢二钠0.4克，调pH至7.4。固体培养基：再加入1.5％琼脂粉，高压蒸气灭菌30min，置于4℃保存)。
取10只小鼠，作为空白对照组。将其余30只小鼠均分为3组：实验组1-2组和模型对照组，每组10只小鼠。实验组1-2组分别给予杠柳苷C和杠柳苷Q灌胃给药，每次80mg/kg。模型对照组和空白对照组均给予等量生理盐水灌胃。实验组1-2组和模型对照组灌胃1h后，均尾静脉注射OD600nm＝0.6化脓性链球菌322171PBS溶液，注射剂量：0.4ml菌液/10g小鼠，每隔24h给药1次，每隔6h观察1次，分别记录时间6h、12h、24h、48h的小鼠的死亡情况。
3、实验结果
各组不同时间对链球菌感染小鼠死亡的影响如表3所示。
表3各组对链球菌感染小鼠死亡的影响(n＝10)
由表3可知，(1)给药48小时后，实验组1-2组的小鼠存活率分别为70％和70％，而模型对照组小鼠的存活率仅为20％；这表明，实施例1制备的杠柳苷C和杠柳苷Q能够显著提高链球菌感染小鼠的存活率，对链球菌感染有显著的治疗作用。
4、实验结论
本发明杠柳苷C和杠柳苷Q对链球菌感染有显著的治疗作用。
显然，上述实施例仅仅是为清楚地说明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (6)
1.香加皮C21甾类及其药学上可接受的衍生物在制备IDO抑制剂中的用途；
所述IDO抑制剂用于治疗癌症、阿尔茨海默病、自身免疫性疾病、强直性脊柱炎、细菌感染、白内障、心境障碍、抑郁症或焦虑症；所述药学上可接受的衍生物选自盐、酯、前药或溶剂合物；
所述香加皮C21甾类具有如下所示的结构：
R选自及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物中的至少一种所形成的糖基残基。
2.香加皮C21甾类及其药学上可接受的衍生物在制备治疗IDO介导的色氨酸代谢途径的病理学特征的疾病的药品中的用途，所述疾病为癌症、阿尔茨海默病、自身免疫性疾病、强直性脊柱炎、细菌感染、白内障、心境障碍、抑郁症或焦虑症；所述药学上可接受的衍生物选自盐、酯、前药或溶剂合物；
所述香加皮C21甾类具有如下所示的结构：
R选自及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物、及其乙酰化衍生物中的至少一种所形成的糖基残基。
3.根据权利要求1或2所述的用途，其特征在于，
R为时，所述香加皮C21甾类为杠柳苷C；或者
R为时，所述香加皮C21甾类为杠柳苷D；或者
R为时，所述香加皮C21甾类为杠柳苷O；或者
R为时，所述香加皮C21甾类为杠柳苷P；或者
R为时，所述香加皮C21甾类为杠柳苷Q；或者
R为时，所述香加皮C21甾类为杠柳苷R；或者
R为时，所述香加皮C21甾类为杠柳苷S；或者
R为时，所述香加皮C21甾类为杠柳苷M；或者
R为时，所述香加皮C21甾类为杠柳苷N。
4.根据权利要求1-3任一项所述的用途，其特征在于，不包括以下技术方案：
杠柳苷C及其药学上可接受的衍生物在制备IDO抑制剂中的用途；所述IDO抑制剂用于治疗癌症或自身免疫性疾病；
杠柳苷D及其药学上可接受的衍生物在制备IDO抑制剂中的用途；所述IDO抑制剂用于治疗自身免疫性疾病。
5.根据权利要求1-3任一项所述的用途，其特征在于，不包括以下技术方案：
杠柳苷C及其药学上可接受的衍生物在制备治疗IDO介导的色氨酸代谢途径的病理学特征的疾病的药品中的用途，所述疾病为癌症或自身免疫性疾病；
杠柳苷D及其药学上可接受的衍生物在制备治疗IDO介导的色氨酸代谢途径的病理学特征的疾病的药品中的用途，所述疾病为自身免疫性疾病。
6.根据权利要求1-5任一项所述的用途，其特征在于，所述香加皮C21甾类按照常规工艺，加入常规辅料制成临床上可接受的片剂、胶囊剂、散剂、合剂、丸剂、颗粒剂、糖浆剂、贴膏剂、栓剂、气雾剂、软膏剂或注射剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710292602.2A CN108785316B (zh) | 2017-04-28 | 2017-04-28 | 香加皮c21甾类在制备ido抑制剂中的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710292602.2A CN108785316B (zh) | 2017-04-28 | 2017-04-28 | 香加皮c21甾类在制备ido抑制剂中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108785316A true CN108785316A (zh) | 2018-11-13 |
| CN108785316B CN108785316B (zh) | 2021-02-05 |
Family
ID=64070634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710292602.2A Active CN108785316B (zh) | 2017-04-28 | 2017-04-28 | 香加皮c21甾类在制备ido抑制剂中的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108785316B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113567589A (zh) * | 2021-08-10 | 2021-10-29 | 安领生物医药(苏州)有限公司 | 一种hplc-ms-ms法测定sd大鼠血浆中北五加皮苷n成分含量的方法 |
| WO2021218763A1 (zh) * | 2020-04-30 | 2021-11-04 | 中国科学院上海药物研究所 | 杠柳苷组合物、其制备方法及其在制备治疗自身免疫性疾病的药物中的用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720921A (zh) * | 2005-06-03 | 2006-01-18 | 中国科学院昆明植物研究所 | 抗肿瘤药物组合物，其制备方法和其应用 |
| CN1939324A (zh) * | 2005-09-29 | 2007-04-04 | 中国科学院上海药物研究所 | 杠柳苷a和e的医学用途 |
| CN103025362A (zh) * | 2010-05-27 | 2013-04-03 | 亨莫特克股份公司 | 用由聚合物网眼细密型缠结物构成的包衣来包衣内假体 |
-
2017
- 2017-04-28 CN CN201710292602.2A patent/CN108785316B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720921A (zh) * | 2005-06-03 | 2006-01-18 | 中国科学院昆明植物研究所 | 抗肿瘤药物组合物，其制备方法和其应用 |
| CN1939324A (zh) * | 2005-09-29 | 2007-04-04 | 中国科学院上海药物研究所 | 杠柳苷a和e的医学用途 |
| CN103025362A (zh) * | 2010-05-27 | 2013-04-03 | 亨莫特克股份公司 | 用由聚合物网眼细密型缠结物构成的包衣来包衣内假体 |
Non-Patent Citations (3)
| Title |
|---|
| JIAQUAN FENG 等: "Immunosuppressive pregnane glycosides from Periploca sepium and Periploca forrestii", 《PHYTOCHEMISTRY》 * |
| 李大金主编: "《免疫抑制剂》", 31 December 2005, 复旦大学出版社 * |
| 虎亚光 等主编: "《新编妇幼专科用药速查手册》", 30 April 2016, 甘肃科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021218763A1 (zh) * | 2020-04-30 | 2021-11-04 | 中国科学院上海药物研究所 | 杠柳苷组合物、其制备方法及其在制备治疗自身免疫性疾病的药物中的用途 |
| CN113567589A (zh) * | 2021-08-10 | 2021-10-29 | 安领生物医药(苏州)有限公司 | 一种hplc-ms-ms法测定sd大鼠血浆中北五加皮苷n成分含量的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108785316B (zh) | 2021-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2304770C (en) | A use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds | |
| Liu et al. | An in vivo and in vitro assessment of the anti-inflammatory, antinociceptive, and immunomodulatory activities of Clematis terniflora DC. extract, participation of aurantiamide acetate | |
| TW201623208A (zh) | 牛樟芝化合物、製備方法及其用途 | |
| JP6389958B2 (ja) | 瓦草５環性トリテルペンサポニン類化合物抗腫瘍の薬物用途 | |
| CN108785316A (zh) | 香加皮c21甾类在制备ido抑制剂中的用途 | |
| KR20080107794A (ko) | 우방자 추출물을 함유하는 항암 조성물 | |
| CN108785322A (zh) | 黑骨藤c21甾类在制备ido抑制剂中的用途 | |
| CN108785318A (zh) | 苯丙素苷类化合物在制备ido抑制剂中的用途 | |
| CN112778392A (zh) | 一种绞股蓝化合物在抗肿瘤药物中的应用与制备 | |
| CN107648297A (zh) | 一种黄褐毛忍冬提取物、含有该提取物的制剂及在医药领域的应用 | |
| CN108785317A (zh) | 香加皮c21甾类化合物在制备ido抑制剂中的用途 | |
| CN108785321A (zh) | 黑骨藤c21甾类化合物在制备ido抑制剂中的用途 | |
| CN108785319A (zh) | 苯丙素苷类在制备ido抑制剂中的用途 | |
| KR0183448B1 (ko) | 진세노사이드 Rg5를 함유하는 항암제 조성물 | |
| CN106236792B (zh) | 苦丁茶提取物的制备及抗阿尔兹海默症用途 | |
| CN110092806B (zh) | 附子中具有镇痛作用的c19二萜生物碱糖苷及其用途 | |
| CN108392488A (zh) | 芍药苷在制备ido抑制剂中的用途 | |
| CN108785350A (zh) | 香加皮提取物在制备ido抑制剂中的用途 | |
| CN108785392A (zh) | 桂花提取物在制备ido抑制剂中的用途 | |
| CN112279811A (zh) | C20二萜生物碱、其制备及治疗疼痛相关疾病的用途 | |
| CN101570485B (zh) | 一种长链脂肪酸的糖醇酯及其分离提取方法和在抑制芳香化酶活性中的应用 | |
| CN108997473A (zh) | 一种非海参烷型海参皂苷及其制备方法与应用 | |
| CN104788528B (zh) | 霞草齐墩果烷型五环三萜化合物，含有该化合物的药物组合物及其应用 | |
| CN106963844A (zh) | 番茄水溶性皂苷提取物在制备治疗高尿酸血症药物或保健品中的应用 | |
| CN103980198A (zh) | 生物碱Casuarinine H及其在制备治疗神经退行性疾病药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20181113 Assignee: Jiangsu Jinmao Finance Leasing Co.,Ltd. Assignor: SUZHOU KAIXIANG BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023320010003 Denomination of invention: Application of Cortex Periplocae C21 steroids in the preparation of IDO inhibitors Granted publication date: 20210205 License type: Exclusive License Record date: 20230105 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of Cortex Periplocae C21 steroids in the preparation of IDO inhibitors Effective date of registration: 20230109 Granted publication date: 20210205 Pledgee: Jiangsu Jinmao Finance Leasing Co.,Ltd. Pledgor: SUZHOU KAIXIANG BIOTECHNOLOGY Co.,Ltd. Registration number: Y2023320010020 |
|
| EC01 | Cancellation of recordation of patent licensing contract | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Jiangsu Jinmao Finance Leasing Co.,Ltd. Assignor: SUZHOU KAIXIANG BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023320010003 Date of cancellation: 20240203 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210205 Pledgee: Jiangsu Jinmao Finance Leasing Co.,Ltd. Pledgor: SUZHOU KAIXIANG BIOTECHNOLOGY Co.,Ltd. Registration number: Y2023320010020 |